Assessment of the efficacy and toxicity of 131I- metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours

British Journal of Cancer

Volumn 98, Issue 6, 2008, Pages 1053-1058

  Nwosu, A C ^a   Jones, L ^b   Vora, J ^b   Poston, G J ^b   Vinjamuri, S ^b   Pritchard, D M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

131I MIBG; Carcinoid; Neuroendocrine; Radionuclide

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; PENTETREOTIDE IN 111; POTASSIUM IODATE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARCINOID SYNDROME; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY DISEASE; LETHARGY; LEUKOPENIA; LUNG CANCER; MALE; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PANCREAS CANCER; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT RESPONSE; VOMITING;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS;

EID: 40849106624     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604273     Document Type: Article

References (22)

1. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31: 1038-1046
2. 131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 26: 969-976
3. Castellani MR, Alessi A, Savelli G, Bombardieri E (2003) The role of radionuclide therapy in medullary thyroid cancer. Tumori 89: 560-562
4. 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44: 77-87
5. 131I-MIBG). Ann N Y Acad Sci 1073: 465-490
6. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J (2006) Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 26: 703-707
7. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch CE (2006) Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140: 968-976
8. 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 44: 232-239
9. Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, Forssell-Aronsson E, Nilsson O (2003) Uptake of metaiodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89: 1383-1388
10. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25: 1054-1060
11. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128: 1717-1751
12. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97: 934-959
13. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55: 47-60
14. 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136: 1218-1226
15. Pathirana AA, Vinjamuri S, Byrne C, Ghaneh P, Vora J, Poston GJ (2001) (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 27: 404-408
16. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle FG, Ruszniewski P, Ahlman H, Wiedenmann B (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80: 394-424
17. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K, Watkinson A (2005) Guidelines for the management of gastroentero-pancreatic neuroendocrine (including carcinoid) tumours. Gut 54(Suppl 4): iv1-16
18. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 239-248
19. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, Tyler DS, Olson Jr JA (2004) Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101: 1987-1993
20. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight Jr GS, Tyler DS, Olson Jr JA (2003) Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956-962
21. Sywak MS, Pasieka JL, McEwan A, Kline G, Rorstad O (2004) I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 28: 1157-1162
22. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH (1994) Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21: 545-559